Kainos Medicine카이노스메드

Kainos Medicine remains deeply loss-making, and recent filings flag investment-caution designation and an adverse audit opinion.

Kainos Medicine is a Korean biotech that develops drugs for hard-to-treat diseases and earns money mainly by licensing candidates to partners. In the trailing twelve months to H1 2026 it reported revenue of about ₩1.4B against an operating loss of about ₩5.9B, and cash of about ₩0.7B. Its market value at the latest close is about ₩36B.

What stands out

• Trailing revenue is about ₩1.4B, while operating loss is about ₩5.9B and free cash flow is about -₩3.8B, so the business is burning cash heavily.
• Revenue rose about 98.5% in 2025 to ₩1.17B, but the operating loss widened to about ₩6.4B and net loss to about ₩7.8B.
• Cash of about ₩0.7B is small relative to the trailing cash burn; the data does not show any new financing.
• Filings on 14 August 2026 mention an investment-caution designation, a adverse audit opinion on the half-year review, and an equity-impairment condition.
• Two contract terminations were filed on 29 May 2026, and the company has no price-based valuation multiple because earnings are negative.

What to watch

• Whether the company announces new financing, asset sales or capital measures, given the cash position and the audit and capital-impairment filings.
• Any update on the investment-caution designation and the listing-eligibility review mentioned in the August filings.
• Progress of the Parkinson's candidate in U.S. trials and any new licensing milestones or royalty income; the data does not include a dated timeline.